HUTCHMED Launches Phase III Trial for HMPL-760 Targeting Relapsed/Refractory DLBCL in China
HUTCHMED has announced the initiation of a Phase III clinical trial for HMPL-760, a novel treatment for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China. This trial aims to evaluate the efficacy and safety of HMPL-760, potentially offering new hope for patients battling this aggressive form of cancer.